According to DelveInsight’s latest publication, “Facioscapulohumeral Muscular Dystrophy Pipeline Insight 2026“, the therapeutic landscape of Facioscapulohumeral Muscular Dystrophy (FSHD) is witnessing substantial advancements, with more than 10 leading biopharmaceutical companies actively developing over 12 pipeline therapies targeting this rare genetic muscle disorder.
The report delivers comprehensive insights into the current clinical and non-clinical pipeline ecosystem, highlighting emerging therapies, ongoing clinical trials, mechanism of action analysis, collaborations, licensing activities, and future commercialization opportunities in the FSHD treatment market.
Discover the latest clinical developments and emerging therapies in the Facioscapulohumeral Muscular Dystrophy pipeline landscape
Key Takeaways from the Facioscapulohumeral Muscular Dystrophy Pipeline Report
• DelveInsight identifies a robust pipeline landscape featuring 10+ active companies and 12+ therapeutic candidates under development for FSHD treatment.
• Major companies involved in the FSHD pipeline include Avidity Biosciences, Hoffmann-La Roche, Arrowhead Pharmaceuticals, Epicrispr Biotechnologies, Dyne Therapeutics, and others.
• Promising therapies in development include EPI-321, AOC 1020, RO7204239, ARO-DUX4, Losmapimod oral tablet, MYO-029, and ATYR1940.
• Therapies are being evaluated across multiple modalities, including gene therapies, monoclonal antibodies, RNA interference technologies, peptides, and small molecules.
Facioscapulohumeral Muscular Dystrophy Recent Clinical Developments
• In November 2026, Epicrispr Biotechnologies announced a clinical study evaluating the safety, tolerability, and early efficacy signals of EPI-321 in adult male and female patients aged 18-75 years diagnosed with FSHD Type 1.
• In November 2026, Hoffmann-La Roche initiated a clinical trial assessing the pharmacodynamics, safety, tolerability, pharmacokinetics, and efficacy of RO7204239, a humanized monoclonal antibody targeting latent myostatin, in ambulatory adult FSHD patients.
Stay updated on the latest Facioscapulohumeral Muscular Dystrophy clinical trials
Facioscapulohumeral Muscular Dystrophy Overview
Facioscapulohumeral Muscular Dystrophy (FSHD) is a rare inherited neuromuscular disorder characterized by progressive skeletal muscle weakness and wasting. The disease predominantly affects muscles of the face, shoulders, upper arms, trunk, and lower limbs.
FSHD is primarily associated with abnormal activation of the DUX4 gene located on chromosome 4, resulting in muscle cell toxicity and degeneration over time. Symptoms often begin during adolescence or early adulthood and progressively impair physical function and quality of life.
Common symptoms include:
• Difficulty smiling or whistling
• Weakness in facial muscles
• Shoulder blade protrusion
• Difficulty lifting arms
• Progressive lower limb weakness
Despite growing research efforts, there remains a significant unmet medical need for disease-modifying therapies capable of slowing or reversing disease progression.
Emerging Drugs Profile in the Facioscapulohumeral Muscular Dystrophy Pipeline
• AOC 1020: Avidity Biosciences, Inc.
AOC 1020 is an investigational therapy designed to reduce abnormal DUX4 gene expression, which is considered the primary driver of FSHD pathology. The therapy combines a proprietary monoclonal antibody targeting transferrin receptor 1 (TfR1) with siRNA directed against DUX4 mRNA.
Preclinical studies demonstrated improved muscle strength and prevention of muscle weakness across multiple functional assays. The therapy is currently progressing through Phase III clinical development.
• RO7204239: Hoffmann-La Roche
RO7204239 is a humanized anti-latent myostatin monoclonal antibody utilizing Sequential Monoclonal Antibody Recycling Technology (SMART-Ig). By targeting latent myostatin, the therapy aims to promote muscle growth and improve muscular strength in FSHD patients.
The therapy is currently being evaluated in Phase II clinical trials.
• ARO-DUX4: Arrowhead Pharmaceuticals
ARO-DUX4 is an RNA interference (RNAi)-based therapy developed to specifically silence DUX4 gene expression in patients with FSHD Type 1. The investigational therapy seeks to reduce DUX4-induced muscle toxicity and potentially halt disease progression.
The candidate is currently in Phase I/II clinical development.
Explore comprehensive drug profiles and pipeline intelligence for emerging FSHD therapies
Leading Companies in the Facioscapulohumeral Muscular Dystrophy Pipeline
Key organizations actively shaping the FSHD treatment landscape include:
• Avidity Biosciences Inc.
• Hoffmann-La Roche
• Arrowhead Pharmaceuticals
• Epicrispr Biotechnologies Inc.
• Dyne Therapeutics Inc.
• and several emerging biotechnology innovators
These companies are investing heavily in gene-targeting technologies, RNA therapeutics, and muscle regeneration strategies to address the underlying disease pathology.
Therapeutic Assessment of the FSHD Pipeline
By Route of Administration
Pipeline therapies are being developed across multiple routes of administration, including:
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
By Molecule Type
The FSHD therapeutic pipeline includes diverse molecular approaches such as:
• Recombinant fusion proteins
• Small molecules
• Monoclonal antibodies
• Peptides
• Polymers
• Gene therapies
Key Insights Covered in the Report
The report provides detailed analysis on:
• Clinical and non-clinical pipeline products
• Emerging drug candidates
• Company profiles
• Mechanism of action analysis
• Therapeutic assessment by development stage
• Route of administration and molecule type
• Licensing and collaboration activities
• Funding and investment analysis
• Unmet needs and future opportunities
• Inactive and discontinued pipeline assets
Unveil future treatment opportunities and commercialization trends in the FSHD market landscape
Scope of the Facioscapulohumeral Muscular Dystrophy Pipeline Report
• Coverage: Global
• Companies: Avidity Biosciences Inc., Hoffmann-La Roche, Arrowhead Pharmaceuticals, Epicrispr Biotechnologies Inc., Dyne Therapeutics Inc., and others
• Therapies: EPI-321, AOC 1020, RO7204239, ARO-DUX4, Losmapimod oral tablet, MYO-029, and others
• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Clinical Stages Covered: Discovery, Preclinical, Phase I, Phase II, and Phase III
Table of Contents
1. Introduction
2. Executive Summary
3. Facioscapulohumeral Muscular Dystrophy Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. DelveInsight’s Analytical Perspective
7. Late-Stage Products (Phase III)
8. AOC 1020: Avidity Biosciences, Inc.
9. Mid-Stage Products (Phase II)
10. RO7204239: Hoffmann-La Roche
11. Early-Stage Products (Phase I/II)
12. ARO-DUX4: Arrowhead Pharmaceuticals
13. Preclinical and Discovery Stage Products
14. Inactive Products
15. Key Companies
16. Key Products
17. Unmet Needs
18. Market Drivers and Barriers
19. Future Perspectives and Conclusion
20. Analyst Views
21. Appendix
About Delveinsight
DelveInsight is a leading healthcare-focused market research and consulting firm specializing in life sciences and healthcare intelligence. The company provides actionable market insights, epidemiology forecasts, competitive intelligence, and strategic consulting services to pharmaceutical, biotechnology, and healthcare organizations worldwide. The firm’s research solutions help clients identify emerging opportunities, understand competitive dynamics, and make informed business decisions in rapidly evolving therapeutic markets.
Contact Details
Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: mmalhotra@delveinsight.com
Phone: +91-9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
